Patents Assigned to Schering Corporation
-
Publication number: 20120231003Abstract: Nucleic acids encoding mammalian, e.g., primate, receptors, purified proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described.Type: ApplicationFiled: March 16, 2012Publication date: September 13, 2012Applicants: Medical Research Council, Schering CorporationInventors: A. Neil Barclay, Marion H. Brown, Daniel M. Gorman, Lewis L. Lanier, Gavin J. Wright, Holly Cherwinski, Joseph H. Phillips, Robert M. Hoek, Jonathan D. Sedgwick
-
Publication number: 20120231018Abstract: Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein each variable in Formula 1 are as defined in the specification; and pharmaceutical compositions comprising the compounds of formula I. Also disclosed are methods of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases, and the methods of inhibiting of Human Immunodeficiency Virus, plasmepins, cathepsin D and protozoal enzymes. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic m1 agonist or m2 antagonist.Type: ApplicationFiled: March 9, 2012Publication date: September 13, 2012Applicants: Pharmacopeia Inc., Schering CorporationInventors: Zhaoning Zhu, Brian McKittrick, Zhong-Yue Sun, Yuanzan C. Ye, Johannes H. Voigt, Corey O. Strickland, Elizabeth M. Smith, Andrew Stamford, William J. Greenlee, Robert D. Mozzola, John P. Caldwell, Jared N. Cumming, Lingyan Wang, Yusheng Wu, Ulrich Iserloh, Xiaoxiang Liu, Tao Guo, Thuy X. E. Le, Kurt W. Saionz, Suresh D. Babu, Rachael C. Hunter, Michelle L. Morris, Huizhong Gu, Gang Qian, Dawit Tadesse, Ying Huang, Guoqing Li, Jianping Pan, Jeffrey A. Misiaszek, Gaifa Lai, Jingqi Duo, Chuanxing Qu, Yuefei Shao
-
Publication number: 20120231017Abstract: Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein each variable in Formula 1 are as defined in the specification; and pharmaceutical compositions comprising the compounds of formula I. Also disclosed are methods of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases, and the methods of inhibiting of Human Immunodeficiency Virus, plasmepins, cathepsin D and protozoal enzymes. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic m1 agonist or m2 antagonist.Type: ApplicationFiled: March 8, 2012Publication date: September 13, 2012Applicants: Pharmacopeia Inc., Schering CorporationInventors: ZHAONING ZHU, Brian McKittrick, Zhong-Yue Sun, Yuanzan C. Ye, Johannes H. Voigt, Corey O. Strickland, Elizabeth M. Smith, Andrew Stamford, William J. Greenlee, Robert D. Mozzola, John P. Caldwell, Jared N. Cumming, Lingyan Wang, Yusheng Wu, Ulrich Iserloh, Xiaoiang Liu, Tao Guo, Thuy X. E. Le, Kurt W. Sainoz, Suresh D. Babu, Rachael C. Hunter, Michelle L. Morris, Huizhong Gu, Gang Qian, Dawit Tadesse, Ying Huang, Guoqing Li, Jianping Pan, Jeffrey A. Misiaszek, Gaifa Lai, Jingqi Duo, Chuanxing Qu, Yuefei Shao
-
Patent number: 8263070Abstract: Provided are methods for modulating activity of the immune system using agonists or antagonists of a CD200 receptor. Also provided are methods of treatment and diagnosis of immune disorders.Type: GrantFiled: March 10, 2008Date of Patent: September 11, 2012Assignee: Schering CorporationInventors: Holly M. Cherwinski, Michael E. Bigler, Jonathon D. Sedgwick, Joseph H. Phillips
-
Patent number: 8263080Abstract: Provided are methods of modulating cytokine activity, e.g., for the purpose of treating viral infections. Also provided are reagents for use in screening for agonists or antagonists of IL-23.Type: GrantFiled: February 15, 2005Date of Patent: September 11, 2012Assignee: Schering CorporationInventors: Peter D. Katsikis, Ioannis Dimitriou, Daniel J. Cua
-
Patent number: 8263748Abstract: The present invention provides lyophilized formulations of antibodies, such as antibodies that specifically bind to human interleukin-23 p19 (IL-23p19), or antigen binding fragments thereof.Type: GrantFiled: August 25, 2009Date of Patent: September 11, 2012Assignee: Schering CorporationInventors: Xuhong Li, Ramesh S. Kashi, Aniket Badkar
-
Publication number: 20120225030Abstract: Provided are cytokines and methods of modulating activity of the immune system using cytokine agonists and antagonists. Also provided are methods of treatment of immune and proliferative disorders.Type: ApplicationFiled: May 14, 2012Publication date: September 6, 2012Applicant: Schering CorporationInventors: Rene de Waal Malefyt, Marilyn Travis, Elena Vaisberg
-
Publication number: 20120225482Abstract: Nucleic acids encoding a new family of chemokines, the CX3C family, from a mammal, reagents related thereto, including specific antibodies, and purified proteins are described. Methods of using said reagents and related diagnostic kits are also provided.Type: ApplicationFiled: April 23, 2012Publication date: September 6, 2012Applicant: Schering CorporationInventors: Gerard T. Hardiman, Devora L. Rossi, Kevin B. Bacon, Bazan Fernando J., Thomas P. Schall, Albert Zlotnik
-
Patent number: 8257921Abstract: The present invention provides, in part, methods for identifying inhibitors of NRIP1 and methods of using such inhibitors. Methods of treating NRIP1-mediated disorders using NRIP1 inhibitor are also provided.Type: GrantFiled: December 22, 2009Date of Patent: September 4, 2012Assignee: Schering CorporationInventors: Xiaorui Yao, Scott W. Altmann, Liji Zhu
-
Patent number: 8258319Abstract: This application discloses a novel process for the preparation of himbacine analogs useful as thrombin receptor antagonists. The process is based in part on the use of a base-promoted dynamic epimerization of a chiral nitro center.Type: GrantFiled: June 24, 2011Date of Patent: September 4, 2012Assignee: Schering CorporationInventors: George G. Wu, Anantha Sudhakar, Tao Wang, Ji Xie, Frank X. Chen, Marc Poirier, Mingsheng Huang, Vijay Sabesan, Daw-long Kwok, Jian Cui, Xiaojing Yang, Tiruvettipuram K. Thiruvengadam, Jing Liao, Ilia Zavialov, Hoa N. Nguyen, Ngiap Kie. Lim
-
Publication number: 20120219565Abstract: The invention relates to binding compounds that specifically bind to human TSLP, as well as uses thereof, e.g., in the treatment of inflammatory disorders and allergic inflammatory response.Type: ApplicationFiled: November 2, 2010Publication date: August 30, 2012Applicant: Schering CorporationInventor: Leonard G. Presta
-
Publication number: 20120220769Abstract: A process for preparing 7-[2-[4-(6-fluoro-3-methyl-1,2-benzisoxazol-5-yl)-1-piperazinyl]ethyl]-2-(1-propynyl)-7H-pyrazolo-[4,3-e]-[1,2,4]-triazolo[1,5-c]pyrimidin-5-amine, intermediates useful in that process, and processes for preparing said intermediates are disclosed.Type: ApplicationFiled: August 3, 2010Publication date: August 30, 2012Applicant: Schering CorporationInventors: Shen-Chun Kuo, Yonggang Chen, Jeffrey M. Eckert, William W. Leong, Nanfei Zou, Gabriel C. Kuklis
-
Publication number: 20120208826Abstract: The present invention relates to heterocyclic amide derivatives of Formula (I): Formula (I) wherein the variables are as defined in the specification. The present invention further relates to compositions comprising said heterocyclic amide derivatives of formula (I) and methods for using said heterocyclic amide derivatives of formula (I) for treating or preventing a disease or disorder related to the activity of a protein kinase, in particular, a proliferative disease, an anti-proliferative disorder, inflammation, arthritis, a neurological or neurodegenerative disease, a cardiovascular disease, alopecia, a neuronal disease, an ischemic injury, a viral disease or a fungal infection.Type: ApplicationFiled: August 19, 2010Publication date: August 16, 2012Applicant: SCHERING CORPORATIONInventors: Panduranga Adulla P. Reddy, M. Arshad Siddiqui, Tzu Tshin Wong
-
Publication number: 20120207752Abstract: Provided herein are methods of modulating IL-33 activity, e.g., for the purpose of treating immune diseases and conditions, as well as methods of screening for compounds capable antagonizing IL-33 signaling.Type: ApplicationFiled: April 25, 2012Publication date: August 16, 2012Applicant: Schering CorporationInventors: Alissa A. Chackerian, Robert A. Kastelein
-
Patent number: 8242112Abstract: Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein W is a bond, —C(?S)—, —S(O)—, —S(O)2—, —C(?O)—, —O—, —C(R6)(R7)—, —N(R5)— or —C(?N(R5))—; X is —O—, —N(R5)— or —C(R6)(R7)—; provided that when X is —O—, U is not —O—, —S(O)—, —S(O)2—, —C(?O)— or —C(?NR5)—; U is a bond, —S(O)—, —S(O)2—, —C(O)—, —O—, —P(O)(OR15)—, —C(?NR5)—, —(C(R6)(R7))b— or —N(R5)—; wherein b is 1 or 2; provided that when W is —S(O)—, —S(O)2—, —O—, or —N(R5)—, U is not —S(O)—, —S(O)2—, —O—, or —N(R5)—; provided that when X is —N(R5)— and W is —S(O)—, —S(O)2—, —O—, or —N(R5)—, then U is not a bond; and R1, R2, R3, R4, R5, R6, and R7 are as defined in the specification; and pharmaceutical compositions comprising the compounds of formula I.Type: GrantFiled: May 16, 2011Date of Patent: August 14, 2012Assignees: Schering Corporation, Pharmacopeia Drug Discovery, Inc.Inventors: Zhaoning Zhu, Brian McKittrick, Zhong-Yue Sun, Yuanzan C. Ye, Johannes H. Voigt, Corey Strickland, Elizabeth M. Smith, Andrew W. Stamford, William J. Greenlee, Robert D. Mazzola, Jr., John P. Caldwell, Jared N. Cumming, Lingyan Wang, Yusheng Wu, Ulrich Iserloh, Tao Guo, Thuy X. H. Le, Kurt W. Saionz, Suresh D. Babu, Rachael C. Hunter, Michelle L. Morris, Huizhong Gu, Gang Qian, Dawit Tadesse
-
Publication number: 20120201823Abstract: The present invention provides antagonists of APRIL. In particular, the APRIL antagonists block unique receptor binding sited on APRIL, BCMA. TACI, and/or HSPG. Also provided are methods of use.Type: ApplicationFiled: October 14, 2010Publication date: August 9, 2012Applicant: Schering CorporationInventors: Mary J. Janatpour, Kathy L. Miller
-
Patent number: 8236309Abstract: The invention relates generally to the field of immunology, in particular, to bispecific antibodies. Methods for designing a bispecific antibody for use in treating diseases relating to the immune system are disclosed. Specific examples relate to bispecific antibodies which recognize an activating receptor and an inhibiting receptor.Type: GrantFiled: May 25, 2010Date of Patent: August 7, 2012Assignee: Schering CorporationInventors: Michael Eric Bigler, Holly Marie Cherwinski, Joseph H. Phillips
-
Publication number: 20120195881Abstract: In its many embodiments, the present invention provides certain pentafluorosulfur imino heterocyclic compounds, including compounds Formula (a) and pharmaceutically acceptable salts thereof. Compounds of Formula (a) have the general structure: (a) wherein each variable is selected independently and as defined herein. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use in treating pathologies associated with amyloid beta (A?) protein, including Alzheimers Disease, are also disclosed.Type: ApplicationFiled: October 6, 2010Publication date: August 2, 2012Applicant: Schering CorporationInventors: Ulrich Iserloh, Andrew W. Stamford, Jared N. Cumming
-
Publication number: 20120190696Abstract: The present invention relates to novel heterocyclic compounds as Fatty Acid Binding Protein (FABP) inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose.Type: ApplicationFiled: October 1, 2010Publication date: July 26, 2012Applicant: Schering CorporationInventors: Gerald W. Shipps, JR., Clifford C. Cheng, Xioahua Huang, Abdelghani Achab, Peter Orth, Johannes H. Voigt
-
Publication number: 20120189639Abstract: Antibodies to human GITR are provided, as well as uses thereof, e.g., in treatment of proliferative and immune disorders.Type: ApplicationFiled: August 31, 2010Publication date: July 26, 2012Applicant: Schering CorporationInventors: Xiao Min Schebye, Grigory P. Ermakov, Douglas J. Hodges, Leonard G. Presta